Clinical Research Directory
Browse clinical research sites, groups, and studies.
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Sponsor: University Hospital, Strasbourg, France
Summary
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Official title: Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-04-20
Completion Date
2026-04-20
Last Updated
2026-01-14
Healthy Volunteers
No
Conditions
Locations (1)
Service Oncologie Médicale - CHU de Strasbourg - France
Strasbourg, France